ImmunityBio
IBRX
126 hedge funds and large institutions have $196M invested in ImmunityBio in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 49 increasing their positions, 27 reducing their positions, and 23 closing their positions.
81% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 27
57% more capital invested
Capital invested by funds: $125M → $196M (+$71M)
1.55% more ownership
Funds ownership: 8.32% → 9.86% (+1.5%)
4% less funds holding
Funds holding: 131 → 126 (-5)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
29% less call options, than puts
Call options by funds: $3.06M | Put options by funds: $4.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$21.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.54M |
| 3 |
JP Morgan Chase
New York
|
+$1.83M |
| 4 |
Citigroup
New York
|
+$1.64M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.56M |
| 2 |
Morgan Stanley
New York
|
-$1.53M |
| 3 |
Renaissance Technologies
New York
|
-$1.49M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.05M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$505K |
IBRX Hedge Fund Activity: Q3 2022 in Review
126 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2022, worth a combined $196M — up 57% from $125M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of IBRX and 18 opened new positions — a net loss of 5 holders — while 27 trimmed existing stakes and 49 added.
The largest buyer was State Street, adding an estimated $21.8M. The largest seller was Millennium Management, cutting an estimated $3.56M.
- 126 institutional investors held ImmunityBio (IBRX) as of Q3 2022, down from 131 in Q2 2022.
- Funds reported $196M of ImmunityBio stock for Q3 2022, up 57% quarter-over-quarter.
- 18 funds opened new ImmunityBio positions in Q3 2022 and 23 closed out, a net change of -5 holders.
- The largest ImmunityBio buyer in Q3 2022 was State Street, an estimated $21.8M added.
- The largest ImmunityBio seller in Q3 2022 was Millennium Management, an estimated $3.56M sold.
Based on aggregated 13F filings for Q3 2022.